Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac trial)

Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac trial)

Abstract Background Anogenital warts are the second most common sexually transmitted infection diagnosed in sexual health services in England. About 90% of genital warts are caused by human papillomavirus (HPV) types 6 or 11, and half of episodes diagnosed are recurrences. The best and most cost-eff...

Full description

Bibliographic Details
Main Authors: Macey L. Murray, Jade Meadows, Caroline J. Doré, Andrew J. Copas, Lewis J. Haddow, Charles Lacey, Mark Jit, Kate Soldan, Kate Bennett, Michelle Tetlow, Mayura Nathan, Richard Gilson
Format: Article
Language:English
Published: BMC 2018-11-01
Series:BMC Medical Research Methodology
Subjects:
Podophyllotoxin
Imiquimod
Quadrivalent HPV vaccine
Human papillomavirus
Anogenital warts
Online Access:http://link.springer.com/article/10.1186/s12874-018-0581-z

Internet

http://link.springer.com/article/10.1186/s12874-018-0581-z

Similar Items